CMND Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

0.600

Open

0.600

VWAP

0.56

Vol

329.61K

Mkt Cap

6.22M

Low

0.532

Amount

186.20K

EV/EBITDA(TTM)

--

Total Shares

10.19M

EV

-9.42M

EV/OCF(TTM)

--

P/S(TTM)

--

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Show More

Events Timeline

(ET)

2026-05-05

09:00:00

Clearmind Medicine Files European Patent Application

2026-04-30 (ET)

2026-04-30

16:41:00

Clearmind Medicine Files to Sell 22.63M Common Shares

2026-04-27 (ET)

2026-04-27

07:50:00

Clearmind Medicine Evaluates CMND-100 for FDA Breakthrough Therapy Designation

2026-04-20 (ET)

2026-04-20

16:30:00

Major Averages Decline Amid Escalating Tensions with Iran

2026-04-20

12:00:00

Major Averages Decline Amid Rising Tensions with Iran

2026-04-17 (ET)

2026-04-17

10:00:00

Trump Administration to Examine Ibogaine Drug Safety

2026-04-16 (ET)

2026-04-16

12:10:00

White House Considers Safety Review of Ibogaine

2026-04-16

11:30:00

Clearmind's CMND-100 Meets Primary Safety Endpoint

2026-04-16

10:50:00

Clearmind Medicine Continues CMND-100 Clinical Trial

News

Newsfilter

04-27Newsfilter

Clearmind's Positive Clinical Trial Results May Support Breakthrough Therapy Designation

moomoo

CLEARMIND MEDICINE INC - HAS NOT APPLIED FOR OR BEEN GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR MEAI

NASDAQ.COM

04-21NASDAQ.COM

Clearmind Medicine Reports Positive Clinical Trial Results and Regulatory Support

stocktwits

04-20stocktwits

Trump Signs Executive Order to Accelerate Psychedelic Research

Newsfilter

04-20Newsfilter

Clearmind's Drug Clinical Trial Achieves Success

Yahoo Finance

04-18Yahoo Finance

Trump Administration to Examine Safety of Psychedelic Drug for PTSD

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Intellectia · 16 candidates

Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Outlook Therapeutics Inc

32.35M

Theriva Biologics Inc

11.80M

Cango Inc

198.55M

Silo Pharma Inc

8.38M

Blink Charging Co

99.60M

Cue Biopharma Inc

59.20M

cheapest top moving penny stocks

Intellectia · 16 candidates

Region: USPrice: $0.20 - $5.00Volume: >= 1,000,000Price Change Pct: >= $10.00List Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Enveric Biosciences Inc

4.44M

Theriva Biologics Inc

11.80M

Clearmind Medicine Inc

2.00M

Cue Biopharma Inc

59.20M

Cango Inc

198.55M

TScan Therapeutics Inc

67.71M

stocks under $5 likely to be bullish today

Intellectia · 30 candidates

Price: $0.50 - $5.00Rsi Category: moderatePrice Change Pct: >= $2.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $5.00

Ticker

Name

Market Cap$

JE Cleantech Holdings Ltd

5.26M

Southland Holdings Inc

66.02M

ioneer Ltd

275.18M

Rezolve AI PLC

949.87M

Baozun Inc

121.73M

Skillsoft Corp

34.60M

Low float stock screener

Intellectia · 1484 candidates

List Exchange: XNYS, XNAS, XASEFloating Shares: <= 20,000,000

Ticker

Name

Market Cap$

Lion Group Holding Ltd

638.91K

La Rosa Holdings

711.55K

Erayak Power Solution Group Inc

831.04K

NewGenIvf Group Ltd

864.77K

Quhuo Ltd

948.08K

Biodexa Pharmaceuticals PLC

1.01M

Find stocks with low float

Intellectia · 2888 candidates

Region: USShares Outstanding: <= 150,000,000

Ticker

Name

Market Cap$

Aditxt Inc

2.59M

Greenwave Technology Solutions Inc

4.33M

Golden Heaven Group Holdings Ltd

5.19M

American Rebel Holdings Inc

3.47M

iPower Inc

5.62M

UTime Ltd

1.44M

Whales Holding CMND

Trading Trends

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 0.5626 USD — it has decreased -7.86

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -3.66M USD, increased 144.62

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -2084949.00 USD, increased 64.76

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of May 06 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 6.22M USD.